Related Experiment Video
Updated: Jul 7, 2026

Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug
Published on: December 14, 2021
Comparative pharmacokinetics of amikacin in Greyhound and Beagle dogs
1Department of Anatomy and Physiology, PharmCATS, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA. kukanich@ksu.edu
Abstract:
The purpose of the study was to compare the pharmacokinetics of amikacin administered i.v., to Greyhound and Beagle dogs and determine amikacin pharmacokinetics administered subcutaneously to Greyhounds. Amikacin was administered i.v. at 10 mg/kg to six healthy Greyhounds and six healthy Beagles. The Greyhounds also received amikacin, 10 mg/kg s.c. Plasma was sampled at predetermined time points and amikacin concentrations determined by a fluorescence polarization immunoassay (FPIA). The volume of distribution was significantly smaller in Greyhounds (mean = 176.5 mL/kg) compared to Beagles (234.0 mL/kg). The C(0) and AUC were significantly larger in Greyhounds (86.03 microg/mL and 79.97 h x microg/mL) compared to Beagles (69.97 microg/mL and 50.04 h x microg/mL). The plasma clearance was significantly lower in Greyhounds (2.08 mL/min/kg) compared to Beagles (3.33 mL/min/kg). The fraction of the dose absorbed after s.c. administration to Greyhounds was 0.91, the mean absorption time was 0.87 h, and the mean maximum plasma concentration was 27.40 microg/mL at 0.64 h. Significant differences in the pharmacokinetics of amikacin in Greyhounds indicate it should be administered at a lower dose compared to Beagles. The dose in Greyhounds to achieve a C(max):AUC >or= 8 for bacteria (with an MIC
More Related Videos
10:30Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
Published on: May 24, 2016
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
Estimation of k and VD of Aminoglycosides
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Dosage Regimens: Partial Pharmacokinetic Parameters